molecules of the month


potential BIC oral GCS inhibitor

Ph. III in genetic diseases (15 mg QD)

brain-penetrant, allosteric inhibitor

Scientific Reports


Chemical structure of molecule Venglustat Sanofi glucosylceramide synthase (GCS) inhibitor
1 min read

The Sanofi glucosylceramide synthase (GCS) inhibitor, venglustat, is an oral, brain-penetrant clinical candidate for GBA-mutant Parkinson’s disease and other diseases where GBA-mutations are relevant. Though the molecule did not demonstrate efficacy within one year in early GBA-PD patients and was discontinued in this indication (NCT02906020), it continues to be tested in various rare genetic diseases including Gaucher disease type 3 (NCT02843035), Fabry disease (NCT02228460), GM2 gangliosidosis (NCT04421451), and autosomal-dominant polycystic kidney disease (NCT04705051), as its safety has already been demonstrated.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: